H-Index
34
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
call: +1.631.629.4327
Mon-Fri 10 am - 2 pm EST

Logo

MSMbanner
Medical Science Monitor Basic Research

AmJCaseRep
MedSciTechnol

eISSN: 2329-0358

Perioperative Single High Dose ATG-Fresenius S Administration as Induction Immunosuppressive Therapy in Cadaveric Renal Transplantation- Preliminary Results

Radoslaw Samsel, Andrzej Chmura, Zbigniew Wlodarczyk, Janusz Wyzgal, Tomasz Cieciura, Jacek Pliszczynski, Grazyna Korczak, Tomasz Lazowski, Leszek Paczek, Janusz Walaszewski, Mieczyslaw Lao, Wojciech Rowinski

Ann Transplant 1999; 4(2): 37-39

ID: 497453

Available online: 1999-06-11

Published: 1999-06-11


Monoclonal and polyclonal antilymphocyte antibodies have been used successfully in organ transplantation as induction therapy and in the treatment of acute graft rejection. Used for induction the medication is generally given for the first 7-10 days. The aim of this study was to assess the safety and efficacy of single high dose (9 mg/kg) ATG Fresenius Sgiven perioperatively, before revascularization, to kidney allograft recipients. During last twelve months seventy six, first cadaveric kidney adult recipients were included into the study in two centers (center A-64, center 8-12). All patients received triple drug immunosuppression(Neoral. steroids and Cellcept which was replaced by azathioprine after 4 months). and were randomized to receive ATG or not. The follow-up period ranged from I month up to I year. The preliminary results are very promising. the rejection rate in bolus group was significantly lower than in control. No significant side effects or serious adverse events in both groups were observed.

Keywords: Atg, Kidney Transplantation, Immunosuppression, inductiontherapy



Back